Cosmo Pharmaceuticals : announces European approval of Qolotag® for sigmoidoscopies in IBD patients

Dublin - July 26, 2017 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that its medical device Qolotag® has been granted the CE mark and the approval for marketing in the EU.

Qolotag® is a liquid, blue coloured emulsion developed by Cosmo as an enema formulation to be used for the mechanical cleansing, and simultaneous staining, of the sigmoid colon and rectal mucosa to aid visualization of the structure and mucosal lesions by the endoscopist during flexible sigmoidoscopy evaluation. The product is a single packaged, ready to use enema formulation based on a Cosmo proprietary technology, and exerts a double action: it softens the faeces, allowing an easy bowel emptying and cleaning prior to the endoscopy, and meanwhile adheres to the mucosal walls, maximising the contact time between the dye (methylene blue) and the mucosa, for an improved staining. These product features allow for a faster and better enhancement of the detection of eventual small lesions or dysplasias.

Long-term IBD patients generally are monitored with endoscopic system for evaluating the activity of the disease and for dysplasia detection.

Cosmo intends to license Qolotag® for the EU and is currently assessing the regulatory pathway for an approval in the USA.

Alessandro Della Chà, CEO of Cosmo, commented: 'This product was developed following a specific request by the gastroenterologists, to enable them an in-depth assessment of dysplasia in Inflammatory Bowel Disease patients, who do not wish to pursue the more expensive, invasive and cumbersome procedure of a colonoscopy. Qolotag®, the second innovative medical device product after Eleview® entirely developed by Cosmo to support the endoscopy line, will help to further expand our approved product offering within our gastrointestinal franchise to provide innovative solutions on unmet medical needs'.

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal Disorders and Endoscopic Procedures. The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn's Disease, and Colon Infections. In addition, the Company has developed a medical device for polyp and adenoma excision and is has completed clinical trials of LuMeBlue™, a diagnostic drug for the detection of colon cancer as well as new chemical entities that are being developed by the associate company Cassiopea S.p.A. for the topical treatment of skin diseases. Cosmo's MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Santarus/Salix/Valeant and in the Rest of the World to Ferring as Cortiment®. Cosmo's proprietary MMX® technology is at the core of the Company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon. For further information on Cosmo, please visit the Company's website: www.cosmopharma.com

Next events

Half-Year Report 2017July 28, 2017

Contact

John Manieri, Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 (1) 8170 370 jmanieri@cosmopharma.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an 'offer of securities to the public' within the meaning of Directive 2003/71/EC of the European Union (the 'Prospectus Directive') of the securities referred to in it (the 'Securities') in any member state of the European Economic Area (the 'EEA'). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.